Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clinical Trials Flood India But Infrastructure Woes Stifle Cancer Trials

This article was originally published in PharmAsia News

Executive Summary

AHMEDABAD, India - As the number of clinical trials grow steadily in India to reach over $1 billion in turnover, a peculiar "problem of plenty" faces clinical trials for specialized cancer drugs

You may also be interested in...



Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages

India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.

Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages

India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.

Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility

MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants

UsernamePublicRestriction

Register

GB150366

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel